Eli Lilly and Co at Sanford C Bernstein Operational Decisions Conference (Virtual) Transcript
Hi, everybody, and thank you for joining us today. In this session of the ODC, we have a special treat for you. Kevin and the Eli Lilly IR team were kind enough to let us have a conversation today with 3 of their scientific leader: Andrew Adams, who runs the new therapeutic area modalities and also the COVID-19 section; Mark Mintun, I hope I'm not ruining your name too much, the VP of neurodegeneration and pain and himself quite a notable neurodegeneration scientist; and Jeff Emmick, who is the VP of diabetes products development, in charge on, I guess, all the clinical side of diabetes products and a few other related areas.
So what we've designed is probably a bit of a too long of a conversation with each one of them for the next 45 minutes. I'll try to kind of stay 15 minutes per topic. The first discussion will be around COVID, then neurodegeneration and diabetes will close us up.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
